Mvasi

Random entry RSS

Posted in:
Legal

District Judge Dismisses Amgen’s Declaratory Judgment Suit Over Avastin® Biosimilar
By D. Lawson Allen February 7, 2018 Comments are off
On February 2, 2018, U.S. District Judge George H. Wu granted Genentech’s motion to dismiss a complaint brought by Amgen in the Central...

Read more

Tagged with: Amgen, Avastin®, bevacizumab, bevacizumab-awwb, BPCIA, Genentech, Mvasi

http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:
Legal

Litigation vs. Licensing: Manufacturers of the Two Most Recently Approved Biosimilars Take Different Approaches to Reference Drug Patents
By Benjamin R. Holt December 5, 2017 Comments are off
The FDA has only approved eight biosimilar products to date. The second most recently approved biosimilar is Mvasi (bevacizumab-awwb),...

Read more

Tagged with: Amgen, Avastin®, bevacizumab, Biocon, BPCIA, FDA, Genentech, Herceptin®, Mvasi, Mylan, Ogivri

http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
ShareEmail, Linked In, Twitter, Facebook, Google Plus

Back to Top